Answers are grounded in this paper and cite their sources.
In patients with euvolemic or hypervolemic hyponatremia, tolvaptan, an oral vasopressin V2-receptor antagonist, was effective in increasing serum sodium concentrations at day 4 and day 30. (ClinicalTrials.gov numbers, NCT00072683 [ClinicalTrials.gov] [SALT-1] and NCT00201994 [ClinicalTrials.gov] [SALT-2].).
No takes yet. Share an insight, caveat, or question.
Schrier et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: